Advanced search
Start date
Betweenand

Preventive effect of the orizanol range on lipid and inflammatory metabolism in the liver of obese rats

Grant number: 19/04524-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): October 01, 2019
Effective date (End): September 30, 2021
Field of knowledge:Health Sciences - Nutrition - Nutrition Biochemistry
Principal Investigator:Camila Renata Corrêa
Grantee:Janaina Paixão das Chagas Silva
Home Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Obesity has been considered the evil of the century in Brazil and in the World. The main associated factor is the uncontrolled consumption of simple sugars, which is associated with the development of metabolic syndrome and its complications. At the same time, liver involvement, an organ of great importance in the metabolism of carbohydrates and lipids, can be caused by the fatty degeneration of this organ, also known as hepatic steatosis or non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease is associated with more severe damage to hepatic tissue, such as steatohepatitis, which is characterized by elevated expression of inflammatory cytokines and can progress to fibrosis, cirrhosis and liver carcinoma. The objective of the study was to verify the preventive effect of orizanol variation in the development of hepatic steatosis, inflammation and beta oxidation in obese animals. The animals will be distributed in four experimental groups (n = 12 animals/group). Groups G1, G2, G3 and G4. The G1 group will receive standard diet (DP), G2 diet standard + ³-orizanol (DP + yOz), G3 diet rich in carbohydrates and fat (DCG) and G4 diet rich in carbohydrates and fat + for 30 weeks. The supply of feed and water will be ad libitum and the consumption of feed and drink controlled daily. To monitor the development of the animal, the body weight will be checked weekly. Caloric consumption, adiposity index, glycemia, triglycerides will be evaluated. Protein quantification of PPAR-± will be done by means of the western blot technique and plasma concentrations of IL-6 and TNF-± and insulin by the ELISA technique. Steatosis will be identified by histological analysis of the liver. The data will be presented by descriptive measures of position and variability and analyzed by ANOVA of two variables.